Open Access
- 11 April 2024
- book chapter
- Published by Springer Nature
- p. 203-210
Abstract
Transfusions are an essential part of supportive care in the context of HCT. RBC and platelet concentrates (PCs) are the main blood products transfused in the peri-transplant period. Here we summarize indication for transfusion, selection of product type and immunohematological challenges in the context of allogeneic stem cell transplantation.Keywords
This publication has 29 references indexed in Scilit:
- Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trialLeukemia Research, 2023
- Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the questionBone Marrow Transplantation, 2020
- Granulocyte transfusions – bridging to allogeneic hematopoietic stem cell transplantationLeukemia & Lymphoma, 2019
- Clinical Practice Guidelines From the AABBJAMA, 2016
- Platelet refractoriness – practical approaches and ongoing dilemmas in patient managementBritish Journal of Haematology, 2015
- The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantationCurrent Opinion in Hematology, 2014
- Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-AnalysisTransplantation and Cellular Therapy, 2014
- A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic CancersNew England Journal of Medicine, 2013
- Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised studyThe Lancet, 2012
- Dose of Prophylactic Platelet Transfusions and Prevention of HemorrhageNew England Journal of Medicine, 2010